SCOPUS 정보 검색 플랫폼

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 5, 2000, Pages 601-606

Technology evaluation: AAV factor IX gene therapy, Avigen Inc

(2) Fabb, S A a Dickson, J G a

a UNIVERSITY OF LONDON (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; COAGULIN B;

CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG RESPONSE; EXPRESSION VECTOR; GENE THERAPY; HEMOPHILIA B; HUMAN; LICENSING; PHASE 1 CLINICAL TRIAL; REVIEW; TECHNOLOGY;

ANIMALS; ANTIBODY FORMATION; BIOTECHNOLOGY; DEPENDOVIRUS; FACTOR IX; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA B; HUMANS; MALE;

EID: 0033750541 PISSN: 14648431 EISSN: None Source Type: Journal
DOI: None Document Type: Review

Times cited : (18)

References (12)

1
- 0027473752
- Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group
- (1993) New Eng J Med , vol.328 , Issue.7 , pp. 453-459
- Lusher, J.M.¹ Arkin, S.² Abildgaard, C.F.³ Schwartz, R.S.⁴ Warrier, I.⁵ Pfaffman, L.⁶ Adedort, L.M.⁷ Forster, A.⁸ Harrison, J.⁹ Pearce, J.M.¹⁰ Ragni, M.¹¹ Miller, B.¹²

2
- 0028266130
- A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group
- (1994) Blood , vol.83 , Issue.9 , pp. 2428-2435
- Bray, G.L.¹ Gomperts, E.D.² Courter, S.³ Gruppo, R.⁴ Gordon, E.M.⁵ Manco-Johnson, M.⁶ Shapiro, A.⁷ Scheibel, E.⁸ White III, G.⁹ Lee, M.¹⁰

3
- 0007328322
- Press release 8 May
- (1997) Promise of Avigen gene therapy

4
- 0007194434
- Press release 28 May
- (1998) Avigen's gene therapy approach shows promise in treating hemophilia B with single intramuscular administration

5
- 4243787045
- AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver
- (1998) American Society of Gene Therapy - First Annual Meeting, Seattle, USA
- Nakai, H.¹ Couto, L.B.² Herzog, R.W.³ Hagstrom, J.N.⁴ Walter, J.⁵ Sung, S.H.⁶ Yang, E.Y.⁷ Tai, S.J.⁸ Iwaki, Y.⁹ Kurtzman, G.J.¹⁰ Colosi, P.¹¹ High, K.A.¹²

6
- 4243792921
- AAV-mediated transfer in dogs with hemophilia B
- (1998) Am Soc Gene Therapy- First Annual Meeting, Seattle, USA
- Herzog, R.W.¹ Yang, E.Y.² Couto, L.B.³ Hagstrom, N.J.⁴ Elwell, D.⁵ Tai, S.J.⁶ Colosi, P.⁷ Podsakoff, G.M.⁸ Read, M.S.⁹ Bellinger, D.A.¹⁰ Brinkhous, K.M.¹¹ Nichols, T.¹² Kurtzman, G.J.¹³ High, K.A.¹⁴

7
- 0007194435
- Press release 10 November
- (1998) Avigen reports the filing of the first IND for gene therapy treatment of hemophilia B

8
- 0007260642
- Press release 4 January
- (1999) Success of gene therapy research for canine hemophilia B shows promise for treating humans

9
- 0007193465
- Press release 24 May
- (1999) Avigen reports FDA regulatory approval to begin hemophilia clinical trial using Coagulin B

10
- 0007316987
- Press release 11 June
- (1999) First hemophilia B patient injected with Avigen's Coagulin-B(TM) in clinical trial at the Children's Hospital of Philadelphia

11
- 4243784544
- Mechanisms underlying adeno-associated virus (rAAV)-mediated gene transfer into human skeletal muscle cells
- Washington DC, USA
- (1999) American Society of Gene Therapy - Second Annual Meeting , Issue.PART IV
- Malik, A.K.¹ Allen, D.L.² Monahan, P.E.³ Samulski, R.J.⁴ Kurachi, K.⁵

12
- 0007189365
- Press release 8 July
- (1999) Avigen secures exclusive worldwide rights to hemophilia B gene therapy technology using adeno-associated virus

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.